Financings in Brief: Baxter
This article was originally published in The Gray Sheet
Baxter: Standard & Poor's revises its "CreditWatch implications" on Baxter's "single A-minus" long-term debt rating and "A-2" commercial paper rating to "positive" from "developing." The revision also applies to unsecured debt ratings for related entities American Hospital Supply Corp., American Hospital Supply Finance Corp., and Baxter Travenol Laboratories. "If the divestiture of its distribution and surgical products business, Allegiance Corp., is completed as currently planned, the long-term debt and commercial paper ratings will be raised to `single A' and `A-1,' respectively," S&P says, noting that the new ratings "will reflect Baxter's strong positions in four specialty medical product markets and its moderate use of debt financing, offset by management's willingness to achieve growth through large acquisitions"...
You may also be interested in...
Health technology assessment body says that while iRhythm Technologies’ Zio XT service improves cardiac arrhythmia detection, more data must be collected to address evidence gaps about its benefit.
UK start-up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country. See what Iceni’s CEO Rob Field said about it here.
The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.